Cargando…

British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy

Detalles Bibliográficos
Autores principales:	Oldroyd, Alexander G S, Lilleker, James B, Amin, Tania, Aragon, Octavio, Bechman, Katie, Cuthbert, Verna, Galloway, James, Gordon, Patrick, Gregory, William J, Gunawardena, Harsha, Hanna, Michael G, Isenberg, David, Jackman, John, Kiely, Patrick D W, Livermore, Polly, Machado, Pedro M, Maillard, Sue, McHugh, Neil, Murphy, Ruth, Pilkington, Clarissa, Prabu, Athiveeraramapandian, Rushe, Phoebe, Spinty, Stefan, Swan, Joanne, Tahir, Hasan, Tansley, Sarah L, Truepenny, Paul, Truepenny, Yvonne, Warrier, Kishore, Yates, Mark, Papadopoulou, Charalampia, Martin, Neil, McCann, Liza, Chinoy, Hector
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398208/ https://www.ncbi.nlm.nih.gov/pubmed/35355064 http://dx.doi.org/10.1093/rheumatology/keac115

Ejemplares similares

Long‐term strength and functional status in inclusion body myositis and identification of trajectory subgroups
por: Oldroyd, Alexander G. S., et al.
Publicado: (2020)

The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort
por: Parker, Matthew J S, et al.
Publicado: (2019)

Applying Hickam’s dictum: a case of adult-onset LGMD2I muscular dystrophy and long QT syndrome
por: Sheikh, Ali S F, et al.
Publicado: (2023)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients
por: Tansley, Sarah L, et al.
Publicado: (2020)

Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results
por: To, Fergus, et al.
Publicado: (2020)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria
por: To, Fergus, et al.
Publicado: (2019)

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2018)

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Patient-centred standards of care for adults with myositis
por: Lilleker, James B., et al.
Publicado: (2017)

The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice
por: Allen, Victoria, et al.
Publicado: (2020)

Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
por: Párraga Prieto, Cristina, et al.
Publicado: (2020)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
por: Yee, Chee-Seng, et al.
Publicado: (2007)

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients
por: Yee, Chee-Seng, et al.
Publicado: (2011)

Numerical scoring for the BILAG-2004 index
por: Yee, Chee-Seng, et al.
Publicado: (2010)

The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally
por: Yee, Chee-Seng, et al.
Publicado: (2012)

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity
por: Yee, Chee-Seng, et al.
Publicado: (2009)

Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods – a qualitative study
por: Oldroyd, Alexander, et al.
Publicado: (2020)

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis
por: Bechman, Katie, et al.
Publicado: (2020)

Numerical scoring for the Classic BILAG index
por: Cresswell, Lynne, et al.
Publicado: (2009)

Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset
por: Tansley, Sarah L., et al.
Publicado: (2014)

The infection risks of JAK inhibition
por: Adas, Maryam A., et al.
Publicado: (2021)

A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2019)

OA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
por: Nguyen, Huong D, et al.
Publicado: (2022)

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies
por: Oldroyd, Alexander G S, et al.
Publicado: (2021)

Corrigendum to: A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies
por: Oldroyd, Alexander G S, et al.
Publicado: (2021)

Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients
por: Betteridge, Z., et al.
Publicado: (2019)

Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app
por: Oldroyd, Alexander G S, et al.
Publicado: (2022)

Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis
por: Parkes, Joanna E., et al.
Publicado: (2018)

Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models
por: Deakin, Claire T, et al.
Publicado: (2020)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

Data quality predicts care quality: findings from a national clinical audit
por: Yates, Mark, et al.
Publicado: (2020)

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies
por: Lilleker, James B, et al.
Publicado: (2018)

Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis: Reply
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v70de7he0ekdfsc6cndijhna95